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Treatment-Resistant Depressed Youth Show
a Higher Response Rate if Treatment Ends
During Summer School Break
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Taryn Mayes, M.S., Martin B. Keller, M.D., David A. Brent, M.D.
Objective: There is little work on the effect of school on response to treatment of depression, with
available research suggesting that children and adolescents with school difficulties are less likely
to respond to fluoxetine compared with those with no school difficulties. Method: Depressed
adolescents in the Treatment of Resistant Depression in Adolescents study, who had not
responded to a previous adequate selective serotonin reuptake inhibitor (SSRI) trial, were
randomly assigned to one of the following: another SSRI, venlafaxine, another SSRI 
cognitive behavior therapy (CBT), or venlafaxine  CBT. Participants were classified into four
groups depending on whether their enrollment in the study and end of treatment was during
school or summer vacation. Results: Controlling for baseline differences, adolescents ending
their 12-week treatment during summer vacation had odds 1.7 times (95% confidence interval 
1.02-2.8, p  .04) greater to have an adequate response as those ending their treatment while
being in school. In addition, adequate depression response was associated with fewer school
problems at week 12 (scores 5 versus scores 5: odds ratio  3.3, 95% confidence interval 
1.9-5.8, p  .001). There was a significant interaction between school difficulties and timing of
treatment, with the lowest rates of response being among adolescents having school difficulties
and ending their treatment during the active school year. Conclusion: School problems are
relevant to treatment response in depressed adolescents and should be incorporated into the
treatment plan. These findings also suggest that the time of the year might need to be taken
into consideration for analysis of clinical trials in school-aged youth. Clinical trial registration
information—Treatment of SSRI-Resistant Depression in Adolescents (TORDIA); http://www.
clinicaltrials.gov; NCT00018902. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(11):1140–1148. Key
Words: adolescent depression, therapy, school problems, time variationl
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oS everal studies have established a relationbetween depression among adolescentsand school related factors such as poor
academic performance,1,2 less connectedness to
school,3 and the teacher’s involvement and de-
pression.2,4 On the other hand, there is little work
on the effect of school factors on response to
treatment of depression. School problems in the 6
months before treatment with fluoxetine in de-
pressed children and adolescents predicted a
This article is discussed in an editorial by Dr. Jeff Q. Bostic onm
page 1095.
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1140 www.jaacap.orgower response rate.5 Because school difficulties
ay precipitate a referral for the treatment of
epression, the timing when treatment is re-
eived may affect outcome. For example, if a
atient began treatment while in school, and
nded acute treatment during the summer, he or
he may show symptomatic improvement that is
n part attributable to being out of school rather
han to treatment per se. In the above-noted
ntidepressant treatment study, patients enrolled
rom the beginning of March to the end of
ugust were seven times more likely to respond
o fluoxetine as compared with those enrolled at
ther times of the year, although timing of treat-
ent did not have any impact on the placebo
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TORDIA SEASONAL VARIATIONresponse.5 These findings suggest that school
stressors, or their relief, may have a strong influ-
ence on treatment response. However, aside from
this report, we did not find any assessment of the
impact of school stress or school attendance on
treatment outcome in adolescent depression.
Therefore, we decided to examine the impact of
school stress and school attendance on treatment
response in the Treatment of SSRI-Resistant De-
pression in Adolescents study (TORDIA), a mul-
tisite randomized treatment study of adolescent
depression.6
In this article, we examine the impact of the
timing of treatment on treatment outcome in the
TORDIA study. We hypothesize that, first, par-
ticipants whose treatment ended during summer
vacation would show a better response rate to
treatment than those for whom their last assess-
ment was during the active school year; second,
that this seasonal difference in response rate
would be particularly pronounced for those who
reported facing difficulties at school; and third,
that remission would be less likely to be sus-
tained in those in whom an adequate clinical
response was assessed while the participant was
on summer vacation.
METHOD
Participants
TORDIA was a six-site, National Institute of Mental
Health–funded study conducted between 2000 and
2006. All 334 participants had clinically significant
major depression by DSM-IV criteria,7 despite a treat-
ment trial with a selective serotonin reuptake inhibitor
(SSRI) for at least 8 weeks, the last 4 weeks of which
were at a dosage that is the equivalent of 40 mg of
fluoxetine. Significant depression was defined as a total
score 40 on the Children’s Depression Rating Scale—
Revised (CDRS-R)8; and a score4 on the Clinical Global
Impressions—Severity Subscale (CGI-S).9
Exclusion criteria were as follows: completion of
two or more adequate SSRI trials; history of nonre-
sponse to an adequate trial of venlafaxine; prior trial of
cognitive behavioral therapy (CBT), with seven or
more sessions; currently taking medication with psy-
choactive properties, excluding some study-allowed
medications at stable doses (6 weeks’ duration);
diagnosis of bipolar I or II disorder, psychosis, autism,
eating disorder, or substance abuse or dependence;
hypertension (diastolic blood pressure 90 mm Hg);
and, for females, pregnancy, breast-feeding, or not
reliably using contraception.
The study was approved by each site’s local insti-
tutional review board. All participants gave informed
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and parents gave informed consent in accordance with
local institutional review board regulations.
As per our hypotheses, we grouped participants
based on whether they ended their treatment during
the school year (S; September to May), or during the
summer vacation (V); those 14 youth whose entire
treatment took place over the summer vacation were
excluded from further analyses. Of those whose treat-
ment ended during the school year, 60 participants
were enrolled when out of school, and 162 participants
had their entire treatment during the school year.
Because these two subgroups’ baseline characteristics,
treatment assignment, and response rates did not
differ (50.0% versus 41.4%, 2  1.3, df  1, p  .25),
they were combined. In addition, 98 participants were
enrolled during the school year but finished treatment
during the school vacation (V).
Randomization and Treatment
Participants were randomly assigned to one of four
treatments after the failed SSRI treatment: switching to
a second SSRI; switching to venlafaxine; switching to a
second SSRI combined with CBT; or switching to
venlafaxine combined with CBT. Randomization was
balanced both within and across sites on incoming
treatment medication, comorbid anxiety, chronic de-
pression (duration 24 months), and suicidal ideation
(Beck Depression Inventory [BDI] item 9 2).10
Cognitive Behavioral Therapy
Therapists who provided CBT had at least a master’s
degree in a mental health field, and had at least 1 year
of prior experience in using this treatment modality.
CBT drew upon the manuals that emphasize cognitive
restructuring and behavior activation, emotion regula-
tion, social skills, and problem solving for participants,
and that also emphasize parent–child sessions to de-
crease criticism and to improve support, family com-
munication, and problem solving.6 The protocol con-
isted of 12 weekly sessions (60-90 minutes each) of
BT, three to six of which were to be family sessions.
median of nine CBT sessions were delivered across
he treatment groups. Therapy audiotapes were re-
iewed using the Cognitive Therapy Rating Scale11 by
on-site supervisors, supervisors in Pittsburgh, and one
external consultant, with a high proportion (93.9%)
rated as acceptable.
Pharmacotherapy
Participants in the SSRI switch groups who were
initially treated with citalopram, sertraline, or fluvox-
amine were randomized to receive either fluoxetine or
paroxetine. If they were initially treated with fluox-
etine, they were switched to receive paroxetine and
vice versa. After the Food and Drug Administration
1141www.jaacap.org
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SHAMSEDDEEN et al.(FDA) warnings on paroxetine, citalopram was used
instead. The SSRI dosage was 10 mg per day for the
first week and 20 mg per day for weeks 2 to 6, with an
option to increase to 40 mg per day if there was
insufficient clinical improvement (CGI-I 3). The ven-
lafaxine dosages for weeks 1 to 4 were 37.5, 75, 112.5,
and 150 mg, respectively, with an option to increase to
225 mg at week 6. If intolerable adverse effects devel-
oped after a medication increase, the participant’s
dosage was lowered to either 20 mg of an SSRI or to
150 mg of venlafaxine.
Pharmacotherapists were either psychiatrists or mas-
ter’s degree–nurses working with the supervision of a
psychiatrist. The study psychiatrist examined partici-
pants at entry, 6 weeks, and 12 weeks. Medication
sessions were 30 to 60 minutes in duration and included
assessment of vital signs, adverse effects, safety, and
symptomatic response, and occurred weekly for the first
4 weeks and every other week thereafter.
Blinding Procedure
The intent was for study participants and clinicians to
be blinded to medication treatment assignment and for
an independent evaluator (IE) to be blinded to both
medication and CBT assignment. Blinding for medica-
tion was maintained by use of three encapsulated pills
daily for all prescriptions, some of which might be
placebo to mask drug type and dose. The blinding to
CBT for IE was maintained by scheduling the IE’s
assessments at a time not contiguous with CBT ses-
sions and by asking participants and staff not to
discuss CBT treatment assignment when the IE was
present. In 64 cases, the blinding of the IE was com-
promised, most commonly because of participant dis-
closure of receiving CBT, although results were similar
after controlling for the effects of unblinding.6
Outcome and Measures
The primary outcome, “adequate clinical response” at
week 12, was defined as a 50% reduction in CDRS-R
score and Clinical Global Impressions—Improvement
Subscale (CGI-I) score of 2 or less. The CDRS-R, a
measure of depression symptom severity based on
separate interviews of the child and parent, is a 17-
item scale, which results in total scores ranging from
17 to 113, with a total score of 40 or greater indicating
significant depression.12 The CGI-I is a measure of
clinical improvement, on a scale of 1 (very much
improved) to 7 (very much worse9). Both the CDRS
and CGI-I were completed by an independent evalu-
ator. A total of 33 adolescents (14.9%) in the S group
and 14 adolescents (12.5%) in the V group did not have
week 12 assessment (2  0.34, df  1, p  .56), so
missing data on outcome were not associated with the
timing of the end of treatment.
The adolescents were also assessed for the follow-
ing: hopelessness using the Beck Hopelessness Scale d
JOURN
1142 www.jaacap.orgBHS)13; severity of suicidal ideation by the Suicide
deation Questionnaire—Jr. (SIQ-Jr.)14; substance use–
related impairment by Drug Use Screening Inventory
(DUSI)15; family conflict using the Conflict Behavior
uestionnaire—Adolescent version (CBQ-A)16; social
functioning by the Social Adjustment Scale—Self Re-
port (SAS-SR)17; anxiety by the Screen for Child Anx-
iety Related Disorders—Child Version (SCARED); and
other comorbidities using the Schedule for Affective
Disorders and Schizophrenia for School-Age Children-
Present and Lifetime version.18
Parental depression and anxiety were assessed us-
ing the Beck Depression Inventory (BDI)10 and Beck
Anxiety Inventory (BAI),19 respectively.
School problems were assessed using six items
from the Social Adjustment Scale—Self Report (SAS-
SR).17 The items assessed days missing classes, being
able to keep up with class work, being ashamed of
how school work was done, having arguments with
other students at school, feeling unhappy at school,
and finding school work interesting in the 2 weeks
before the assessment. The score for each item ranged
from 0 (no problem) to 4 (having the problem always
or most of the time). A total score was calculated with
a possible score ranging from 0 to 24 (mean  5.6,
median  5.0, range  0-21). The total score was
missing for 56 participants (16.8%) at week 0 and for
102 participants (30.5%) at week 12. Both week 0 and
week 12 scores were available for 192 participants,
with a significant correlation between the two scores
(r  0.41, p  .001).
Participants completing their SAS-SR in from June
to August were more likely to have missing answers
on the school-related items. The missing rate for
SAS-SR at enrollment was 19.8% for the S group and
10.2% for the V group (2  4.5, df  1, p  .03),
hereas the missing rate at week 12 was 23.4% in the
group and 42.9% in the V group (2  12.4, df  1,
p  .001).
Having missing SAS-SR school problem scores at
week 0 was not associated with either age (p  .43),
gender (p .35), race (p .54), site (p .32), treatment
assignment (p  .73), type of antidepressant (p  .73),
or CDRS (p .09), CGAS (p .37), and CGI-S (p .14)
baseline scores. In addition, there was no statistically
significant difference between those with missing
scores and those with available scores with respect to
adequate response at week 12 (41.1% versus 48.9%,
2  1.1, df  1, p  .28). Among the V group, having
issing SAS-SR scores at week 0 was not associated
ith response rates at week 12 (40.0% versus 61.4%,
2  1.7, df  1, p  .20).
On the other hand, participants with missing
SAS-SR school scores at week 12, compared with those
with available scores, were older (16.2  1.6 versus
15.7  1.5 years, t  2.4, df  332, p  .02), had higher
aseline CDRS (61.2  10.4 versus 57.7  10.2, t  2.7,
f  332, p  .01) and CGI-S scores (4.6  0.7 versus
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TORDIA SEASONAL VARIATION4.4  0.7, t  2.2, df  174.2, p  .04), and had lower
baseline CGAS scores (49.2  8.3 versus 51.2  7.4, t 
2.1, df  172.4, p  .04). In addition, they were more
likely to be assigned to an SSRI switch rather than to
venlafaxine (63.7% versus 44.4%, 2  10.6, df  1, p 
.001); there was no difference with respect to CBT
assignment (p  .08). There was no statistically signif-
icant association between missing SAS-SR school prob-
lem scores at week 12 with gender (p  .76), race (p 
0.16), or site (p .06). There was no difference between
the two groups regarding response rate at week 12
(41.2% versus 50.4%, 2  2.4, df  1, p  .12). Finally,
among the V group, missing SAS-SR scores at week 12
were not associated with response rates (54.8% versus
62.5%, 2  0.6, df  1, p  .44).
Statistical Analysis
The Statistical Package for Social Sciences (SPSS 14.0)
was used to conduct statistical analysis. Patients were
classified into two treatment time periods depending
on whether their enrollment upon entry and at the end
of acute treatment was during school (S; September–
May) or out of school, during summer vacation (V;
June–August). Pearson 2, independent-sample t test,
and nonparametric tests were conducted to examine
the baseline variables associated with timing of treat-
ment. The Mann–Whitney U test was conducted to
examine differences regarding ordinal variables such
as number of CBT and pharmacotherapy sessions;
however, because the median for pharmacotherapy
session did not differ between groups, the mean and
standard deviation are presented as well. Baseline
variables significantly associated with timing of treat-
ment were controlled for in a multivariable binary
logistic regression with response to treatment being
the outcome.
An independent-sample t test was conducted to
examine whether school difficulty scores, at initiation
and end of treatment, were significantly associated
with timing of the treatment and adequate response at
week 12. Because of the high missing rate on those
scores, a separate multivariable binary logistic regres-
sion was conducted to examine the relation between
timing of treatment and school problems, on one hand,
and adequate response, on the other hand, while
controlling to type of treatment. In this model, the
school problems variable was categorized into two
groups using median split. Values of p  .05 were
considered to be statistically significant.
RESULTS
Timing of Treatment
The V group had a higher rate of adequate
response as compared with the S group (59.2%
versus 40.8%, odds ratio [OR]  1.9, 95% confi- S
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tion therapy, compared with monotherapy, was
significantly associated with higher rates of ade-
uate response among the V group (70.0%
ersus 47.9%, 2  4.9, df  1, p  .03) but not
in the S group (49.1% versus 38.6%, 2  2.5,
f  1. p  .12).
Controlling for Site and Baseline Differences
There was no significant association between the
time period of the treatment and any demo-
graphic characteristics (Table 1). The V group,
compared with the S group, had higher SCARED
total score (32.2  14.9 versus 28.4  16.2, t 
2.0, df  314, p  .05). In particular, the V
group had higher scores on the following sub-
scales: generalized anxiety disorder (9.9  4.1
versus 8.8  5.0, t  2.1, df  225, p  .04),
separation anxiety disorder (4.2  3.6 versus
3.1 3.0, t2.6, df 160.8, p .01), and social
anxiety disorder (7.3  4.2 versus 6.2  4.2, t 
2.1, df  313, p  .04). There was no difference
between the two groups with respect to any of
the other clinical characteristics. Moreover, time
of treatment was not associated with either that
parental psychopathology (depression and anxi-
ety) or family environment. In addition, there
was no difference between the two groups with
respect to being switched to an SSRI or venlafax-
ine (p  .47), or the type of SSRI they were
switched to (p  .80). However, there was a
ignificant difference with respect to number of
harmacotherapy visits (median, nine for both
roups, Mann–Whitney z2.5, p .01; mean
D, S  7.7  2.3 versus V  8.3  1.8) but not
umber of CBT sessions (p .30). Controlling for
emographic characteristics (age, gender, race,
nd family income), site, treatment assignment,
CARED total scores, and number of pharmaco-
herapy visits, the V group was 1.8 times (95%
I  1.03-3.31, p  .04) as likely to show ade-
uate response as the S group. Upon adding
nteraction terms to the logistic regression model,
iming of treatment had no significant interaction
ith assignment to combination therapy (p  .21),
ype of antidepressant the participants were
witched to (p  .11), or SCARED scores (p  .81).
To examine the possible effect of seasonal
ffective disorders, which might interact with
atitude, sites were split into northern (Pittsburgh,
rown, and Portland) and southern (Dallas, Los
ngeles, and Galveston) sites. Controlling for site,
CARED, and number of pharmacotherapy visits,
1143www.jaacap.org
SHAMSEDDEEN et al.TABLE 1 Demographic and Clinical Characteristics of Study Participants, by Season
Characteristic Sa (N  222) Vb (N  98) p
Demographic characteristic
Age (y), mean  SD) 15.8  1.6 16.0  1.5 .25
Sex, n (%) female 159 (71.6) 66 (67.3) .44
Race, n (%) white) 179 (80.6) 85 (86.7) .19
Parent education, n (%) college graduate) 104 (49.5) 43 (45.7) .62
Income (thousands of dollars, median (range) 67 (0–500) 55 (8–200) .17
Clinical characteristic (mean  SD)
Children’s Depression Rating Scale 59.9  10.4 59.3  10.7 .72
Clinical Global Impressions Severity 4.5  0.6 4.5  0.7 .67
Children’s Global Assessment Scale 50.8  7.7 50.0  7.8 .40
Beck Depression Inventory 20.8  12.3 20.7  11.9 .94
Age at onset of current MDD (y) 13.9  2.3 13.9  2.0 .87
Duration of depression (mo) 22.0  20.7 22.6  19.3 .46
Beck Hopelessness Scale 10.5  5.7 10.8  5.4 .62
DUSI impairment 11.1  18.0 11.2  21.0 .41
Social Adjustment Scale—Self Report 36.5  13.4 37.2  13.1 .69
Comorbidity, n (%)
Anxiety, including PTSD 76 (34.9) 37 (38.5) .53
PTSD 16 (7.2) 8 (8.2) .77
Attention-deficit/hyperactivity disorder 33 (15.0) 16 (16.5) .73
Oppositional defiant/conduct disorder 24 (11.0) 8 (8.2) .44
Dysthymia 70 (31.8) 24 (24.7) .20
History of physical abuse 28 (12.7) 11 (11.5) .74
History of sexual abuse 35 (16.1) 17 (18.1) .66
SCARED (mean  SD)
Panic disorder 7.2  6.2 7.6  5.6 .52
Generalized anxiety disorder 8.8  5.0 9.9  4.1 .04
Separation anxiety disorder 3.1  3.0 4.2  3.6 .01
Social anxiety disorder 6.2  4.2 7.3  4.2 .04
Significant school avoidance 3.1  2.3 3.1  2.2 .83
Total score 28.4  16.2 32.2  14.9 .05
Suicidality/self-injury
History of suicide attempt, n (%) 57 (25.7) 20 (20.6) .33
SIQ-Jr Suicidal Ideation (mean  SD) 41.5  22.6 42.7  22.3 .68
Nonsuicidal self injury, n (%) 88 (40.4) 34 (35.4) .41
Parental Psychopathology (mean  SD)
Beck Depression Inventory 9.1  9.0 10.1  9.3 .37
Beck Anxiety Inventory 8.9  9.0 8.7  8.3 .87
Family environment (Mean  SD)
Conflict behavior—adolescent report 9.4  6.2 8.1  6.0 .10
Conflict behavior—parent report 9.8  5.9 8.5  5.9 .08
Treatment assigned, n (%)
SSRI 108 (48.6) 52 (53.1) .47
Venlafaxine 114 (51.4) 46 (46.9)
Combination therapy 114 (51.4) 48 (49.0) .70
Monotherapy 108 (48.6) 50 (51.0)
Treatment received
No. of PT visits, median (range)c 9 (1–14) 9 (2–10) .01
No. of CBT sessions, median (range) 9 (0–15) 10 (0–14) .30
Adequate response, n (%) 97 (43.7%) 58 (59.2%) .01
Note: CBT  cognitive-behavioral therapy; DUSI  Drug Use Screening Inventory; MDD  major depressive disorder; PT  pharmacotherapy; PTSD 
posttraumatic stress disorder; SCARED  Screen for Child Anxiety Related Emotional Disorders; SIQ-Jr  Suicide Ideation Questionnaire—Jr.; SSRI 
selective serotonin reuptake inhibitor.
aS denotes enrolled in treatment while out of school and ended treatment during school, or enrolled and ended treatment while in school.
bV denotes enrolled in treatment during school and ended treatment while out of school.
cMann–Whitney U test was conducted because the pharmacotherapy (PT) is an ordinal variable; however, because the medians were the same, themean  SD are presented: S  7.7  2.3 versus V  8.3  1.8.
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TORDIA SEASONAL VARIATIONthe V group was 1.7 times (95% CI  1.03-2.8, p 
.04) as likely to show adequate response as the S
group. Moreover, there was no significant inter-
action between timing of treatment and site in
predicting outcome (p  .22), indicating that
timing of treatment had same effect in the north-
ern and southern sites. In addition, participants
were screened for seasonal affective disorder at
baseline and subsequent time points, and only
two participants were found to have this
disorder.
School problems at week 0 were not associated
with either response at week 12 (responders:
9.1  4.6 versus non responders: 9.0  4.3, t 
0.2, df  276, p  .81) or timing of treatment (S:
9.0  4.5 versus V: 9.4  4.4, t  0.7, df  264,
p .50). However, responders, as compared with
nonresponders, had significantly fewer school
problems at week 12 (4.0  3.2 versus 7.2  4.7,
t  5.8, df  204.1, p  .001). Also, V participants
reported fewer school problems than S partici-
pants (4.4 3.9 versus 6.1 4.4, t 2.5, df 224,
p  .01).
In a multivariable logistic regression, adequate
response at week 12 was associated with lower
school problem scores at week 12 (SAS-SR school
difficulty scores 5 versus scores 5: OR  3.2,
95% CI  1.7-5.8, p  .001) and being assigned to
CBT (CBT versus no CBT: OR  1.8, 95% CI 
1.03-3.3, p  .04), but not to type of pharmaco-
therapy (SSRI versus venlafaxine: OR  0.9 , 95%
CI  0.5-1.7, p  .83) or timing of treatment (V
versus S: OR  1.5, 95% CI  0.7-2.9, p  .29).
There was no significant interaction between
school problems and being assigned to CBT (p 
.63) or type of pharmacotherapy (p  .81); how-
ever, there was significant interaction between
school problems and timing of treatment (p 
.01). Upon adding the interaction term between
school problems and timing of treatment to the
model, the following were significantly associ-
ated with adequate response: being assigned to
CBT (OR  1.9 , 95% CI  1.1-3.5, p  .03), lower
school problem scores (OR  4.9, 95% CI 
2.4-10.2, p  .001), V group membership (OR 
3.6, 95% CI  1.3-10.0, p  .01), and the interac-
tion term of timing by school problems at week
12 (OR  0.2, 95% CI  0.05-0.7, p  .01).
To understand this interaction, we examined
the relationship between school difficulties in
response in both the S and V groups. Among the
S youth, those with lower school difficulty scores
(scores 5) were more likely to show response at
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igher school difficulty scores, i.e., SAS-SR
chool difficulty scores 5 (68.0% versus 30.5%,
2 23.6, df 1, p .001; Figure 1). On the other
and, among the V youth, who ended their
reatment while out of school, there was no
ignificant association between school problem
cores and response to treatment (SAS-SR school
ifficulty scores 5: 61.8% versus scores 5:
3.6%, 2  0.02, df  1, p  .89; Figure 1). In
other words, although there was no significant
association between timing of treatment and re-
sponse among participants with low school dif-
ficulty (S versus V, 68% versus 61.8% ; 2  0.2,
f  1, p  .52), among participants with higher
chool difficulty (scores 5), ending treatment,
hile in school was associated with lower rates
f response as compared with ending treatment
hile being out of school (S versus V, 30.5%
ersus 63.3%, 2  8.4, df  1, p  .004).
Sensitivity analyses were conducted to deter-
mine whether SAS-SR missing values could have
affected our results. The V group had a higher
rate of adequate response as compared with the S
group regardless of whether the week 12 SAS-SR
scores were missing (54.8% versus 32.7%, 2 
4.6, df  1, p  .03) or not missing (62.5% versus
7.1%, 2  4.0, df  1, p  .047).
Remission at Week 24
The overall 24-week remission rate for S and V
FIGURE 1 Response rate by treatment timing stratified
by school problems at week 12. School problems
assessed with six items from the Social Adjustment
Scale—Self Report.were 36.0% and 46.9%, respectively (2  3.4,
1145www.jaacap.org
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SHAMSEDDEEN et al.df  1, p  .07). Among those who showed an
adequate response to treatment at week 12, the
24-week remission rates for S versus V were
58.8% and 63.8%, respectively (2  0.4, df  1,
p  .54).
DISCUSSION
In this study, we confirmed our hypotheses as
follows: first, response rates to treatment were
higher if treatment began during the school year,
but ended during vacation, compared with rates
in those participants whose treatment ended dur-
ing the school year; second, school problems
interacted with treatment timing with respect to
outcome, so that the timing of treatment favored
ending treatment out of school only in those
participants who reported greater school prob-
lems at the end of treatment; and third, among
those participants who showed an adequate re-
sponse at week 12, the remission rate at 24 weeks
was similar for both groups.
These results should be considered within the
context of limitations and strengths of this study.
First, this study reports on “post hoc” hypotheses
that were not part of the original study design.
This raises the possibility of having false-positive
results because of multiple hypothesis testing.
Therefore, these findings should be validated by
a study specifically designed to test them. Sec-
ond, we did not document the exact time when
participants’ schooling ended but instead as-
sumed that, on average, participants were out
of school during the summer months. Some of
these students may have been attending summer
school or been in school districts that began
school toward the end of August. Third, patients
were not randomized based on time of start of
treatment. However, the few baseline differences
between the S and V groups were taken into
consideration. Fourth, academic performance, in-
telligence quotient scores, and other school envi-
ronment variables, such as being bullied in
school or the quality of relationships with teach-
ers, were not collected for this study. Fifth, school
problems scores were missing for approximately
one-third of the sample, although missingness of
this variable did not appear to be a confounder
for our findings. Sixth, the causal direction of the
relationship between poor response and school
problems cannot be determined. On the other
hand, this is only the second study that has
examined the timing of treatment with respect to a
JOURN
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reported school difficulties and response to treat-
ment for youth mental health problems.
The effect of timing of treatment on response
to treatment is most likely related to school
stressors that were not present at the time of the
final assessment for those participants who were
out of school. This includes such school stressors
as poor academic performance,1,2 low connected-
ness to school,3 and teacher performance,2,4 all of
which have been found to be associated with
depression and its severity among adolescents.
Such stressors could affect the course of the
treatment if they had not been addressed by the
therapist. For those adolescents whose treatment
ended in the summer, those stressors could have
had less impact. Consistent with this viewpoint,
the relationship between the timing of the ending
of treatment and treatment response was signif-
icant only in those participants who had higher
numbers of school problems, and that overall,
higher numbers of school problems at the end of
treatment was associated with a poorer response
rate. These findings are mostly consistent with
those of Kowatch et al., who reported that pa-
tients with school difficulties in the 6 months
before enrollment in the study were five times
less likely to respond to fluoxetine as those
without school difficulties.5 However, our rat-
ngs of school problems at the beginning of
reatment, 3 months before assessment of re-
ponse, were not related to treatment outcome.
School difficulties could be confounded with
omorbid diagnoses such as conduct, oppositional
isorders, or anxiety disorders. In TORDIA, nei-
her adequate response to treatment nor timing
f the treatment was associated with conduct
isorder or oppositional defiant disorder. In ad-
ition, even after controlling for anxiety, adoles-
ents who were enrolled in the study during
chool and ended treatment while out of school
id better than those who had the whole course
f treatment during school or were enrolled
hile they were out of school and ended treat-
ent during school. Moreover, an anxiety disor-
er diagnosis did not interact with timing of
reatment in predicting adequate response at
eek 12, which indicates that effect of timing of
nd of treatment on response was the same
mong those with and without anxiety disorders.
herefore, although school refusal and other
chool difficulties are associated with depression,
nxiety, conduct disorder, and oppositional defi-
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VOLUME 50 NUMBER 11 NOVEMBER 2011
TORDIA SEASONAL VARIATIONant disorder, the variation in response reported
here does not seem to be associated with any of
these conditions.20
On the other hand, these findings could be
attributable to a biologic effect mediated by sea-
sonal variation in available sunlight. For exam-
ple, in post mortem and in vivo studies, winter
and low amount of sun exposure are associated
with lower levels and lower turnover of sero-
tonin.21,22 However, in TORDIA, participants
were screened for seasonal affective disorder,
and only two participants met criteria at baseline.
Moreover, the latitude of the site did not interact
with timing of the end of treatment with respect
to response.
Whether this relation is caused by school or
seasonal factors, these findings have both clinical
and research implications. School difficulties are
relevant to treatment response, and these find-
ings suggest that clinicians should carefully as-
sess and monitor reported school difficulties and
performance as part of treatment. Intervention
with schools, to diminish school stressors, to
obtain accommodation to the patient’s clinical
status, and to optimize performance should be
part of the treatment plan of every depressed
adolescent. In clinical settings, when an adoles-
cent’s course of treatment ends while the patient
is out of school, the clinician should make sure to
follow up the patient during the next school year,
even if the patient has shown an adequate re-
sponse to therapy. Regarding research, these
findings suggest that the time of the year might
need to be taken into consideration in the design
and analyses of clinical trials of the treatment of
depression in school-aged youth. &
adolescents with SSRI-resistant depression: the TORDIA random-
ized controlled trial. JAMA. 2008;299:901-913.
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